A group of researchers from the Dana-Farber Cancer Institute (MA, USA) has conducted the largest clinical study to date of genetic abnormalities in pediatric brain tumors. The study, published recently in Neuro-Oncology, highlighted that testing for genetic irregularities is clinically feasible and that the results could help guide patients’ treatment.
Restricted Content / Members Only
This content is available to members; it’s free to become a member. If you’re already a member, please login.